Taiwan · Delayed Price · Currency is TWD PharmaEssentia Statistics
Total Valuation
PharmaEssentia has a market cap or net worth of TWD 640.30 billion. The enterprise value is 616.85 billion.
| Market Cap | 640.30B |
| Enterprise Value | 616.85B |
Important Dates
The next estimated earnings date is Monday, November 9, 2026.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | Jul 9, 2026 |
Share Statistics
PharmaEssentia has 414.43 million shares outstanding. The number of shares has increased by 0.22% in one year.
| Current Share Class | 414.43M |
| Shares Outstanding | 414.43M |
| Shares Change (YoY) | +0.22% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 8.05% |
| Owned by Institutions (%) | 10.42% |
| Float | 330.54M |
Valuation Ratios
The trailing PE ratio is 83.52 and the forward PE ratio is 49.67.
| PE Ratio | 83.52 |
| Forward PE | 49.67 |
| PS Ratio | 30.85 |
| PB Ratio | 17.39 |
| P/TBV Ratio | 18.03 |
| P/FCF Ratio | 107.92 |
| P/OCF Ratio | 77.38 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 73.81, with an EV/FCF ratio of 103.97.
| EV / Earnings | 80.86 |
| EV / Sales | 29.73 |
| EV / EBITDA | 73.81 |
| EV / EBIT | 77.51 |
| EV / FCF | 103.97 |
Financial Position
The company has a current ratio of 5.28, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.28 |
| Quick Ratio | 4.76 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.12 |
| Debt / FCF | 0.17 |
| Interest Coverage | 362.61 |
Financial Efficiency
Return on equity (ROE) is 23.34% and return on invested capital (ROIC) is 55.13%.
| Return on Equity (ROE) | 23.34% |
| Return on Assets (ROA) | 12.95% |
| Return on Invested Capital (ROIC) | 55.13% |
| Return on Capital Employed (ROCE) | 21.11% |
| Weighted Average Cost of Capital (WACC) | 7.60% |
| Revenue Per Employee | 158.41M |
| Profits Per Employee | 58.24M |
| Employee Count | 131 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.52 |
Taxes
In the past 12 months, PharmaEssentia has paid 1.33 billion in taxes.
| Income Tax | 1.33B |
| Effective Tax Rate | 14.86% |
Stock Price Statistics
The stock price has increased by +295.15% in the last 52 weeks. The beta is 0.61, so PharmaEssentia's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | +295.15% |
| 50-Day Moving Average | 1,262.76 |
| 200-Day Moving Average | 752.82 |
| Relative Strength Index (RSI) | 69.10 |
| Average Volume (20 Days) | 3,909,973 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaEssentia had revenue of TWD 20.75 billion and earned 7.63 billion in profits. Earnings per share was 18.50.
| Revenue | 20.75B |
| Gross Profit | 18.86B |
| Operating Income | 7.97B |
| Pretax Income | 8.96B |
| Net Income | 7.63B |
| EBITDA | 8.14B |
| EBIT | 7.97B |
| Earnings Per Share (EPS) | 18.50 |
Balance Sheet
The company has 24.47 billion in cash and 1.02 billion in debt, with a net cash position of 23.45 billion or 56.58 per share.
| Cash & Cash Equivalents | 24.47B |
| Total Debt | 1.02B |
| Net Cash | 23.45B |
| Net Cash Per Share | 56.58 |
| Equity (Book Value) | 36.82B |
| Book Value Per Share | 88.84 |
| Working Capital | 27.22B |
Cash Flow
In the last 12 months, operating cash flow was 8.27 billion and capital expenditures -2.34 billion, giving a free cash flow of 5.93 billion.
| Operating Cash Flow | 8.27B |
| Capital Expenditures | -2.34B |
| Depreciation & Amortization | 175.62M |
| Net Borrowing | -224.70M |
| Free Cash Flow | 5.93B |
| FCF Per Share | 14.32 |
Margins
Gross margin is 90.90%, with operating and profit margins of 38.39% and 36.76%.
| Gross Margin | 90.90% |
| Operating Margin | 38.39% |
| Pretax Margin | 43.18% |
| Profit Margin | 36.76% |
| EBITDA Margin | 39.24% |
| EBIT Margin | 38.39% |
| FCF Margin | 28.59% |
Dividends & Yields
This stock pays an annual dividend of 1.35, which amounts to a dividend yield of 0.09%.
| Dividend Per Share | 1.35 |
| Dividend Yield | 0.09% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 4.80% |
| Buyback Yield | -0.22% |
| Shareholder Yield | -0.13% |
| Earnings Yield | 1.19% |
| FCF Yield | 0.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for PharmaEssentia is 1,341.89, which is -13.15% lower than the current price. The consensus rating is "Buy".
| Price Target | 1,341.89 |
| Price Target Difference | -13.15% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 31.55% |
| EPS Growth Forecast (3Y) | 38.24% |
Stock Splits
The last stock split was on July 9, 2026. It was a forward split with a ratio of 1.10927783.
| Last Split Date | Jul 9, 2026 |
| Split Type | Forward |
| Split Ratio | 1.10927783 |
Scores
PharmaEssentia has an Altman Z-Score of 20.64 and a Piotroski F-Score of 7.
| Altman Z-Score | 20.64 |
| Piotroski F-Score | 7 |